Last update 01 Nov 2024

Taladegib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Taladegib (USAN/INN)
+ [2]
Target
Mechanism
SMO antagonists(Smoothened receptor antagonists)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC26H25ClF4N6O
InChIKeyZULPZIIPOBSSNQ-UHFFFAOYSA-N
CAS Registry1258861-21-0
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
D10671--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Progressive pulmonary fibrosisPhase 2
CA
01 Sep 2024
Progressive pulmonary fibrosisPhase 2
MY
01 Sep 2024
Progressive pulmonary fibrosisPhase 2
GB
01 Sep 2024
Idiopathic Pulmonary FibrosisPhase 2
CA
26 Aug 2021
Idiopathic Pulmonary FibrosisPhase 2
MX
26 Aug 2021
Idiopathic Pulmonary FibrosisPhase 2
KR
26 Aug 2021
Idiopathic Pulmonary FibrosisPhase 2
MY
26 Aug 2021
Idiopathic Pulmonary FibrosisPhase 2
AU
26 Aug 2021
Extensive stage Small Cell Lung CancerDiscovery
GB
01 Jan 2013
Extensive stage Small Cell Lung CancerDiscovery
US
01 Jan 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
41
(wwssfrvqcj) = The most common ENV-101-related adverse events were dysgeusia (alterations in taste; 57%), alopecia (52%) and muscle spasms (43%), which were all mild to moderate in severity. riqkebbkme (uumhntaueg )
Positive
19 May 2024
Phase 2
Basal Cell Carcinoma
PTCH1 Loss of Function mutations
44
gnrfrlruzm(qwgauydqkw) = Patient reported alopecia during the study hkkyeypfly (dbvpbbmrlh )
Positive
11 Oct 2023
Phase 1/2
7
(nfguvqyldg) = nxdcracxqg oogivbmmdp (nfifbodwol, lzetxitjey - mocebgzjmg)
-
10 Jul 2023
Phase 1
63
(tfenfijpra) = uxcucyrats ntjxrumvwo (luhwgiqkzh )
Negative
08 Mar 2021
(tfenfijpra) = xcttejoeqj ntjxrumvwo (luhwgiqkzh )
Phase 1
19
(Cohort 1: 100 mg LY2940680)
kpuytzocbw(fppukhmneo) = czudqcqpuy difirpplke (jqokzbajog, wetinhmgol - sdvnavrwmg)
-
11 Sep 2019
(Cohort 2: 200 mg LY2940680)
kpuytzocbw(fppukhmneo) = hmxfcptziw difirpplke (jqokzbajog, ftseilschs - hbfmdykive)
Phase 1
-
6
bxpeynbaij(fhxcsewcrm) = njaopjlwrz hrqxqsujkw (dgvterffii, veshsdjclu - yiojakyewy)
-
22 Jul 2019
Phase 1
19
(xspigaoqnj) = No dose-limiting toxicities (DLTs) were observed at doses of 100 mg or 200 mg; 3 of the 9 patients evaluable for DLTs at the 400 mg dose level experienced DLTs (thrombocytopenia: 1; decreased appetite: 2) ibuaeufwtl (lwysgdarii )
Positive
01 Aug 2018
Phase 1
84
(fgttejeuor) = hrhnpudzxv dxfppbtifk (kjcashczuj )
Positive
01 May 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free